Deal or No Deal?
A closer look at the dynamics shaping the next generation of biotech–pharma partnerships.
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
Deep Dive:
Patients and Partnerships 2025
Dear Readers,
Change may be inevitable, but in pharma, it’s rarely predictable. This year, it has felt constant – a steady hum of reinvention running through every part of the industry. New collaborations. Shifting policies. Evolving ideas of value. The signs are everywhere. Yet, behind the headlines, one truth holds firm: it’s patients who feel the impact most.
Amid all this upset and movement lies a rare kind of opportunity – the chance to turn the idea of true patient-pharma partnership from aspiration into action. Because change, when met with openness, doesn’t just unsettle old systems; it reveals space for new ways of thinking and working together.
In this issue, we take a look at what that shift means in practice, from the evolution of patient support programmes and the rise of patient-led partnerships to the financial and policy shifts redrawing access to care.
At its heart, this issue encapsulates the strength found in working alongside the people who understand the stakes best. Because progress doesn’t happen in isolation. And the future of healthcare belongs to those who listen deeply, collaborate boldly, and move forward together.
Happy reading
Eloise McLennan
Deep Dive editor
Contents
How DTP became pharma’s newest battleground
How to land a deal with big pharma
Beyond being heard: The patient voice as a force for change
Measuring what matters: Rethinking success in patient engagement
Driving change in inherited cardiac conditions through partnerships
When drug prices collide: How US policy shifts are hitting patients worldwide
What’s powering the next wave of life sciences investment in the UK and Nordics?
Rethinking the legacy of patient support programmes
Making Alzheimer’s care more human: A conversation with Lilly’s Hanna Svanbäck
Supercharge your pharma insights: Sign up to pharmaphorum's newsletter for daily updates, weekly roundups, and in-depth analysis across all industry sectors.
